Ofev
| Chemical Name | nintedanib |
| Dosage Form | Capsule (oral; 100 mg, 150 mg) |
| Drug Class | Kinase inhibitors |
| System | Respiratory |
| Company | Boehringer Ingelheim |
| Approval Year | 2014 |
Indication
- For the treatment of idiopathic pulmonary fibrosis (IPF).
- For the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- For the slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).